Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470882 · ClinicalTrials.gov registry record · NA
Use of Safety Behaviors in Exposure Therapy for Arachnophobia
A NA study, sponsored by University of Nevada, Reno.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT04470882: Completed NA study, sponsored by University of Nevada, Reno.
NCT04470882 is a NA study that has completed, run by University of Nevada, Reno. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04470882, a NA study, has completed, sponsored by University of Nevada, Reno.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study examines the impact of safety behaviors (i.e., unnecessary protective actions) on outcomes of exposure therapy for spider phobia. Researchers will compare exposure therapy with (a) no safety behaviors, (b) safety behaviors faded toward the end of treatment, and (c) unfaded safety behaviors.
Primary Outcome
Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time. During this BAT, investigators will assess fear response behaviorally by recording the most challenging step completed (range, steps 0 -12).
Interventions
- BEHAVIORAL Exposure with faded safety behaviors
- BEHAVIORAL Exposure without safety behaviors
- BEHAVIORAL Exposure with unfaded safety behaviors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2020-04-06 |
| Phase | NA |
What the finished NCT04470882 record still lists
NCT04470882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Exposure with faded safety behaviors is the first listed.
NCT04470882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04470882 about?
NCT04470882 is a clinical study titled "Use of Safety Behaviors in Exposure Therapy for Arachnophobia". This study examines the impact of safety behaviors (i.e., unnecessary protective actions) on outcomes of exposure therapy for spider phobia. Researchers will compare exposure therapy with (a) no safety behaviors, (b) safety behaviors faded toward the end of treatment, and (c) unfaded safety behavior...
What is the current status of trial NCT04470882?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2019-02-28. Estimated completion is 2020-04-06.
What interventions are being tested in trial NCT04470882?
The interventions under investigation include: Exposure with faded safety behaviors (BEHAVIORAL), Exposure without safety behaviors (BEHAVIORAL), Exposure with unfaded safety behaviors (BEHAVIORAL).
Who is sponsoring clinical trial NCT04470882?
This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04470882's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI